• Avenue Therapeutics posted a net loss of $695,000, or $0.21 per share, for the quarter ended March 31, 2026.
• Operating loss narrowed to $714,000 as operating expenses fell to $714,000, reflecting research and development expense of $200,000 and general and administrative expense of $514,000.
• Cash and cash equivalents declined to $2.42 million, with net cash used in operating activities of $438,000.
• Company highlighted February 2026 exclusive worldwide license from Duke University for ATX-04 (clenbuterol) in Pompe disease, with upfront payments totaling about $19,000 and milestone obligations totaling about $15.6 million.
• For IV tramadol, Avenue said it is evaluating feasibility of a Phase 3 safety study agreed with FDA, with initiation subject to obtaining necessary financing or a partnership.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avenue Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-015759), on May 08, 2026, and is solely responsible for the information contained therein.